First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy

Table 1 Baseline characteristics before propensity score matching

Variable	Elderly group: 65-74 yr			Very elderly group: 75+ yr
	Gemcitabine mono,n = 25	GA and FOLFIRINOX, n = 49	P value	Gemcitabine mono,n = 20	GA and FOLFIRINOX, n = 10	P value
Age in year	70.9 ± 3.2	69.2 ± 2.7	0.020a	77.5 (76.8-78.9)	76.5 (75.6-78.8)	0.397
Male	10 (40.0)	40 (81.6)	0.000a	14 (70.0)	7 (70.0)	0.999
Body weight in kg	54.8 ± 9.0	59.8 ± 8.8	0.026a	56.0 (43.1-62.7)	54.3 (49.1-68.3)	0.856
Height in m	1.58 ± 0.09	1.65 ± 0.08	0.001a	1.63 (1.57-1.67)	1.62 (1.56-1.69)	0.979
Body mass index in kg/m2	22.0 ± 2.7	22.1 ± 3.0	0.977	22.1 (20.7-23.5)	21.6 (19.9-24.2)	0.775
Metastasis no > 2	18 (72.0)	23 (46.9)	0.041a	13 (65.0)	4 (40.0)	0.206
Site of metastasis
Liver	18 (72.0)	30 (61.2)	0.256	12 (60.0)	3 (30.0)	0.130
Peritoneal carcinomatosis	10 (40.0)	20 (40.8)	0.574	6 (30.0)	4 (40.0)	0.599
Lung	5 (20.0)	9 (18.4)	0.548	4 (20.0)	2 (20.0)	0.999
Primary tumor site			0.671			0.467
Head	10 (40.0)	26 (53.1)		9 (45.0)	3 (30.0)
Body	10 (40.0)	11 (22.4)		5 (25.0)	3 (30.0)
Tail	5 (20.0)	12 (24.5)		6 (30.0)	4 (40.0)
Biliary stenting due to obstruction	11 (44.0)	20 (40.8)	0.796	6 (30.0)	3 (30.0)	0.999
Tumor burden	81.8 ± 43.3	61.4 ± 32.5	0.025a	81.5 (21.0-159.0)	50.0 (15.0-225.0)	0.109
ECOG performance status			0.007a			0.027a
0	5 (20.0)	22 (44.9)		2 (10.0)	4 (40.0)
1	14 (56.0)	24 (49.0)		10 (50.0)	5 (50.0)
2	6 (24.0)	3 (6.1)		8 (40.0)	1 (10.0)
Diabetes	13 (52.0)	24 (49.0)	0.809	7 (35.0)	2 (20.0)	0.416
Hypertension	10 (40.0)	18 (36.7)	0.788	9 (45.0)	2 (20.0)	0.193
Laboratory findings
White blood cell as /μL	6648.0 ± 2411.7	6793.5 ± 2606.2	0.817	8175.0 (6432.4-10546.6)	7985.0 (5824.6-9631.4)	0.880
Platelet as 103/μL	197.1 ± 68.0	244.6 ± 124.7	0.081	191.5 (168.5-217.5)	243.5 (205.1-291.3)	0.028a
N/L ratio	3.9 ± 3.0	3.4 ± 2.8	0.532	3.91 (3.23-6.49)	2.19 (1.22-4.09)	0.055
Platelet/lymphocyte ratio	159.2 ± 74.5	166.6 ± 90.9	0.724	125.6 (120.5-198.4)	136.1 (94.3-176.3)	0.559
C-related protein in mg/dL	1.9 ± 3.0	1.1 ± 1.9	0.175	1.22 (0.96-4.72)	0.75 (0.12-3.04)	0.448
Albumin in g/dL	3.6 ± 0.7	4.0 ± 0.5	0.005a	3.5 (3.2-3.8)	4.3 (3.9-4.5)	0.001a
Total bilirubin in mg/dL	0.98 ± 1.10	1.31 ± 2.10	0.464	0.49 (0.42-0.78)	0.41 (-0.03-2.14)	0.948
CA 19-9 in U/mL	3448.1 ± 8082.3	11073.9 ± 55832.2	0.501	666.4 (-2198.6-21079.9)	341.7 (-11731.7-33174.5)	0.328

Data are presented as: n (%); mean ± standard deviation; median (95% confidence interval).

^aP < 0.05. ALP: Alkaline phosphatase; CA: Carbohydrate antigen; GA: Gemcitabine plus nab-paclitaxel; N/L ratio: Neutrophil/lymphocyte ratio.